Roles of histone methyl-modifying enzymes in development and progression of cancer

Cancer Science

Volumn 104, Issue 7, 2013, Pages 795-800

  Suzuki, Takeshi ^a   Terashima, Minoru ^a   Tange, Shoichiro ^a   Ishimura, Akihiko ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; FLAVINE ADENINE NUCLEOTIDE; HISTONE DEMETHYLASE; HISTONE H3; HISTONE H4; HISTONE LYSINE METHYLTRANSFERASE; LYSINE;

ACUTE GRANULOCYTIC LEUKEMIA; BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL FATE; CELL LINEAGE; CHRONIC MYELOMONOCYTIC LEUKEMIA; COLORECTAL CANCER; ENZYME ANALYSIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE EXPRESSION; GENE INSERTION; GENETIC SCREENING; GENETIC TRANSCRIPTION; HISTONE METHYLATION; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; MEDULLOBLASTOMA; MELANOMA; MULTIPLE CANCER; MULTIPLE MYELOMA; MUTAGENESIS; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STOMACH CANCER; TUMOR GROWTH; XENOTROPIC MULV RELATED VIRUS;

ANIMALS; DISEASE PROGRESSION; DNA METHYLATION; HISTONE DEMETHYLASES; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; MUTAGENESIS, INSERTIONAL; NEOPLASMS;

EID: 84880748934     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12169     Document Type: Review

References (66)

1. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012; 150: 12-27.
2. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 2012; 22: 9-20.
3. Uren AG, Kool J, Berns A, van Lohuizen M. Retroviral insertional mutagenesis: past, present and future. Oncogene 2005; 24: 7656-72.
4. Suzuki T, Shen H, Akagi K et al. New genes involved in cancer identified by retroviral tagging. Nat Genet 2002; 32: 166-74.
5. Touw IP, Erkeland SJ. Retroviral insertion mutagenesis in mice as a comparative oncogenomics tool to identify disease genes in human leukemia. Mol Ther 2007; 15: 13-19.
6. Mikkers H, Allen J, Knipscheer P et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet 2002; 32: 153-9.
7. Lund AH, Turner G, Trubetskoy A et al. Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat Genet 2002; 32: 160-5.
8. Suzuki T, Minehata K, Akagi K, Jenkins NA, Copeland NG. Tumor suppressor gene identification using retroviral insertional mutagenesis in Blm-deficient mice. EMBO J 2006; 25: 3422-31.
9. Akagi K, Suzuki T, Stephens RM, Jenkins NA, Copeland NG. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res 2004; 32: D523-7.
10. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8: 286-98.
11. Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C. Cancer genetics of epigenetic genes. Hum Mol Genet 2007; 16(Spec No 1): R28-49.
12. Shankar S, Srivastava RK. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol 2008; 615: 261-98.
13. Cloos PA, Christensen J, Agger K, Helin K. Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev 2008; 22: 1115-40.
14. Mosammaparast N, Shi Y. Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Ann Rev Biochem 2010; 79: 155-79.
15. Kooistra SM, Helin K. Molecular mechanisms and potential functions of histone demethylases. Nat Rev Genet 2012; 13: 297-311.
16. Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 2012; 13: 343-57.
17. Barski A, Cuddapah S, Cui K et al. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129: 823-37.
18. Albert M, Helin K. Histone methyltransferases in cancer. Semin Dev Biol 2010; 21: 209-20.
19. Varambally S, Cao Q, Mani RS et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 322: 1695-9.
20. Morin RD, Johnson NA, Severson TM et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181-5.
21. Kondo Y, Shen L, Cheng AS et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008; 40: 741-50.
22. Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-9.
23. Ernst T, Chase AJ, Score J et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722-6.
24. Hoffmann I, Roatsch M, Schmitt ML et al. The role of histone demethylases in cancer therapy. Mol Oncol 2012; 6: 683-703.
25. Ueda R, Suzuki T, Mino K et al. Identification of cell-active lysine specific demethylase 1-selective inhibitors. J Am Chem Soc 2009; 131: 17536-7.
26. Kahl P, Gullotti L, Heukamp LC et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006; 66: 11341-7.
27. Hayami S, Kelly JD, Cho HS et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 2011; 128: 574-86.
28. Schulte JH, Lim S, Schramm A et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res 2009; 69: 2065-71.
29. Wang Y, Zhang H, Chen Y et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 2009; 138: 660-72.
30. Agger K, Cloos PA, Christensen J et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 2007; 449: 731-4.
31. Dalgliesh GL, Furge K, Greenman C et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010; 463: 360-3.
32. van Haaften G, Dalgliesh GL, Davies H et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009; 41: 521-3.
33. Jankowska AM, Makishima H, Tiu RV et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011; 118: 3932-41.
34. Agger K, Cloos PA, Rudkjaer L et al. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev 2009; 23: 1171-6.
35. Barradas M, Anderton E, Acosta JC et al. Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev 2009; 23: 1177-82.
36. Terashima M, Ishimura A, Yoshida M, Suzuki Y, Sugano S, Suzuki T. The tumor suppressor Rb and its related Rbl2 genes are regulated by Utx histone demethylase. Biochem Biophys Res Commun 2010; 399: 238-44.
37. Yang ZQ, Imoto I, Fukuda Y et al. Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer Res 2000; 60: 4735-9.
38. Cloos PA, Christensen J, Agger K et al. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 2006; 442: 307-11.
39. Liu G, Bollig-Fischer A, Kreike B et al. Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene 2009; 28: 4491-500.
40. Northcott PA, Nakahara Y, Wu X et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 2009; 41: 465-72.
41. Rui L, Emre NC, Kruhlak MJ et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 2010; 18: 590-605.
42. Ishimura A, Terashima M, Kimura H et al. Jmjd2c histone demethylase enhances the expression of Mdm2 oncogene. Biochem Biophys Res Commun 2009; 389: 366-71.
43. Toyokawa G, Cho HS, Iwai Y et al. The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6. Cancer Prev Res (Phila) 2011; 4: 2051-61.
44. Lu PJ, Sundquist K, Baeckstrom D et al. A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer. J Biol Chem 1999; 274: 15633-45.
45. Xiang Y, Zhu Z, Han G et al. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci U S A 2007; 104: 19226-31.
46. Hayami S, Yoshimatsu M, Veerakumarasivam A et al. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol Cancer 2010; 9: 59.
47. Yamane K, Tateishi K, Klose RJ et al. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell 2007; 25: 801-12.
48. Zeng J, Ge Z, Wang L et al. The histone demethylase RBP2 Is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. Gastroenterology 2010; 138: 981-92.
49. Hou J, Wu J, Dombkowski A et al. Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer. Am J Transl Res 2012; 4: 247-56.
50. Sharma SV, Lee DY, Li B et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141: 69-80.
51. Yoshida M, Ishimura A, Terashima M et al. PLU1 histone demethylase decreases the expression of KAT5 and enhances the invasive activity of the cells. Biochem J 2011; 437: 555-64.
52. Gorrini C, Squatrito M, Luise C et al. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 2007; 448: 1063-7.
53. Me LL, Vidal F, Gallardo D et al. New p53 related genes in human tumors: significant downregulation in colon and lung carcinomas. Oncol Rep 2006; 16: 603-8.
54. Dong JT, Lamb PW, Rinker-Schaeffer CW et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995; 268: 884-6.
55. Miranti CK. Controlling cell surface dynamics and signaling: how CD82/KAI1 suppresses metastasis. Cell Signal 2009; 21: 196-211.
56. Mallette FA, Richard S. JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5. Cell Rep 2012; 2: 1233-43.
57. Patani N, Jiang WG, Newbold RF, Mokbel K. Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer. Anticancer Res 2011; 31: 4115-25.
58. Yang J, Jubb AM, Pike L et al. The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth. Cancer Res 2010; 70: 6456-66.
59. Tzatsos A, Paskaleva P, Ferrari F et al. KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. J Clin Invest 2013; 123: 727-39.
60. He J, Nguyen AT, Zhang Y. KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. Blood 2011; 117: 3869-80.
61. Frescas D, Guardavaccaro D, Bassermann F, Koyama-Nasu R, Pagano M. JHDM1B/FBXL10 is a nucleolar protein that represses transcription of ribosomal RNA genes. Nature 2007; 450: 309-13.
62. Uemura M, Yamamoto H, Takemasa I et al. Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: in vivo identification from hypoxic tumor cells. Clin Cancer Res 2010; 16: 4636-46.
63. Guo X, Shi M, Sun L et al. The expression of histone demethylase JMJD1A in renal cell carcinoma. Neoplasma 2011; 58: 153-7.
64. Wang GG, Song J, Wang Z et al. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature 2009; 459: 847-51.
65. Roesch A, Becker B, Meyer S et al. Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas. Mod Pathol 2005; 18: 1249-57.
66. Bjorkman M, Ostling P, Harma V et al. Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion. Oncogene 2012; 31: 3444-56.